AMR policy dialogue: driving innovative solutions for antimicrobial discovery

  25 August 2022

Antimicrobial resistance (AMR) is a global strategic priority and sits within the UK Government’s National Risk Register. By 2050, AMR is predicted to cause 10 million deaths, more than cancer. In 2019 alone, there were an estimated 4.95 million deaths associated with bacterial AMR. 

Although global pharmaceutical research and development (R&D) spend continues to increase year on year, research into antimicrobial drug discovery is not currently an attractive commercial investment. This has had two major consequences: an ongoing decline of human capital for R&D in this field, and a decline over the longer term in availability of therapeutically effective antibiotics and other antimicrobial agents.

Concerted and coordinated efforts are needed to translate high-level policy commitments into strategic actions for long-term funding and support for the R&D of new antimicrobials.

Further reading: Evidence Brief
Author(s): Chris Dowson et al
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!